[1] 施云珍,李朝霞,厉景南,等. 乙型肝炎病毒基因类型与干扰素治疗效果关系. 中国基层医药,2009,16（8）:1388-1389.
[2] Itsui Y,Sakamoto N,Kurosaki M,et a1. Expressional screening of interferon stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat,2006,13（10）：690.
[3] Stoop JN,Vander M,Kuipers EJ,et al. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B.Virology,2007,361（1）:141-148.
[4] Janssen HL,van Zonneveld M,Senturk H,et a1. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial.Lancet,2005,365:123-129.
[5] 张雪松,金瑞. 替比夫定单用及与阿德福韦或干扰素联用出现肌病的初步观察. 药物不良反应杂志,2008,10:180-183.
[6] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南. 实用肝脏病杂志,2006,9（1）:8-18.
[7] 李耀才,陈小萍,易聪恒,等. 拉米夫定与干扰素序贯治疗慢性乙型肝炎疗效观察. 中华传染病杂志,2006,24（1）：58-59.
[8] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南.实用肝脏病杂志,2006,9（6）：321-324.
[9] Werle Lapostolle B,Bowden S,Locarnini S,et a1.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology,2004,126:1750-1758.
[10] 罗生强,张玲霞. 2007年美国慢性乙型肝炎诊治推荐意见简介.中华肝脏病杂志,2007,15（6）：477-480.
[11] 经继生,孙宝忠,周华,等. 干扰素单用及联合拉米夫定、阿德福韦、胸腺肽αl治疗e抗原阳性、C基因型慢性乙型肝炎的疗效.肝脏,2009,4:37-139.
[12] 马丽华,王龙益,冯萍. 阿德福韦酯片单用与联合干扰素α-2b治疗慢性乙型肝炎100例. 西部医学,2008,20：311-313.
[13] Ingiliz P,Valantin MA,Thibault V,et a1. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha-2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.Antiv Ther,2008,13:895-900.
[14] Piccolo P,Lenci I,Demelia L,et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther,2009,14:1165-1174. |
